Common Contracts
4 similar Director Agreement contracts by Navidea Biopharmaceuticals, Inc., Osiris Therapeutics, Inc.
DIRECTOR AGREEMENTDirector Agreement • March 28th, 2018 • Osiris Therapeutics, Inc. • Biological products, (no disgnostic substances) • Maryland
This DIRECTOR AGREEMENT is made as of June 23, 2016 (the “Agreement”), by and between Osiris Therapeutics, Inc., a Maryland corporation (the “Company”), and Thomas M. Brandt, Jr. (the “Director”).
DIRECTOR AGREEMENTDirector Agreement • May 10th, 2016 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Delaware
This DIRECTOR AGREEMENT is made as of [DATE] (the “Agreement”), by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and [DIRECTOR NAME], an individual with an address at [DIRECTOR ADDRESS] (the “Director”).
DIRECTOR AGREEMENTDirector Agreement • March 29th, 2016 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Delaware
This DIRECTOR AGREEMENT is made as of March 17, 2016 (the “Agreement”), by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Anthony Fiorino, M.D., Ph.D., an individual with an address 308 Churchill Road, Teaneck, NJ, 07666 (the “Director”).
DIRECTOR AGREEMENTDirector Agreement • March 29th, 2016 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Delaware
This DIRECTOR AGREEMENT is made as of March 15, 2016 (the “Agreement”), by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mark I. Greene, M.D., Ph.D. an individual with an address 300 Righters Mill Road, Penn Valley, PA 19072 (the “Director”).
